Universität zu Köln

Zinzani, P. L., Sasse, S., Radford, J., Gautam, A. and Bonthapally, V. (2016). Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. Crit. Rev. Oncol./Hematol., 104. S. 65 - 71. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-0461

Full text not available from this repository.

Abstract

Brentuximab vedotin was available via named patient program (NPP) to patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma in similar to 60 non-US/Canadian countries, before local approval. Published results were examined recently; through systematic literature review, we identified 12 new NPP publications. Most (10/12) publications included new NPP data describing 8 unique cohorts (N = 480; all R/R HL) and new participating countries. Overall response rates were 58-80%, and complete remission rates were 10-40%. With median follow-up of 9.5-26 months, median progression-free survival was 5-10.5 months and median overall survival (OS) had not been reached in most cohorts; 1- and 2-year OS was 67-76% and 58-67%, respectively. Tolerability was as expected from previous reports. Despite intrinsic bias and heterogeneous cohorts, this update supports previous findings showing comparable efficacy and tolerability of brentuximab vedotin between real-world practice and phase 2 trial results in R/R HL (C) 2016 The Authors. Published by Elsevier Ireland Ltd.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Zinzani, P. L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sasse, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Radford, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gautam, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bonthapally, V. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-268723
DOI:	10.1016/j.critrevonc.2016.04.019
Journal or Publication Title:	Crit. Rev. Oncol./Hematol.
Volume:	104
Page Range:	S. 65 - 71
Date:	2016
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1879-0461
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; PHASE-II; EXPERIENCE; RELAPSE; SGN-35; TURKEY Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/26872